

bsm-52309R**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

NFKB1 Recombinant Rabbit mAb**DATASHEET**

Host: Rabbit	Isotype: IgG	Applications: WB (1:500-2000) IHC-P (1:100-500) IHC-F (1:400-800) IF (1:100-500) Reactivity: Human (predicted: Mouse, Rat) Predicted MW.: 105 kDa Subcellular Location: Cytoplasm ,Nucleus
Clonality: Recombinant	CloneNo.: 12G3	
GeneID: 4790	SWISS: P19838	
Target: NFKB1		
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		
Storage: 1xTBS (pH7.4), 1% BSA, 40% Glycerol and 0.02% Proclin300. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009].		

VALIDATION IMAGES

Sample: Lane 1: Human Raji cell lysates Lane 2: Human MCF-7 cell lysates Lane 3: Human Jurkat cell lysates Lane 4: Human A431 cell lysates Lane 5: Human HeLa cell lysates Primary: Anti-NFKB1 (bsm-52309R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 105 kDa Observed band size: 50,120 kDa

SELECTED CITATIONS

- **[IF=5.2]** Yong Wei. et al. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer. AGING-US. 2024 Mar 31; 16(6): 5387-5411 WB ;Human. 38484140